Brief: FDA Provides Positive Feedback On Acurx's CMC Plan For Phase 3
09/12/2024 13:41
Dec 9 (Reuters) - Acurx Pharmaceuticals ACXP.O :
* ACURX UPDATES PHASE 3 READINESS FOR IBEZAPOLSTAT IN C.
DIFFICILE
INFECTION BASED ON RECENT FDA AND EMA COMMUNICATIONS
* ACURX PHARMACEUTICALS INC - FDA PROVIDES POSITIVE FEEDBACK
ON
ACURX'S CMC PLAN FOR PHASE 3
Source text: ID:nPn6PDJra
Further company coverage: ACXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acurx Pharmaceuticals
See all newsAcurx Pharmaceuticals Q1 net loss narrows as expenses fall
Brief: Acurx Pharmaceuticals To Discuss First Quarter 2026 Financial Results On May 12, 2026 Conference Call And Provide Business Update
Brief: Acurx Pharmaceuticals, Inc. Announces Closing Of Up To $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend
Acurx Pharma Q3 net loss narrows to $2 mln